What is the latest NEPHROPLUS stock price?
The latest stored price for NEPHROPLUS is Rs 624.60 as of 2026-11-03.
gimli
NEPHROPLUS stock AI analysis
NEPHROPLUS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
NEPHROCARE HEALTH SERV L is a small-cap stock in Healthcare. This Gimli page shows the latest available NEPHROPLUS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹624.60
1W return
-1.58%
1M return
-3.75%
3M return
-9.31%
6M return
+18.02%
1Y return
n/a
Market cap
₹6,267.28 cr
PE
73.64
PB
5.61
ROE
+10.01%
ROCE
+16.24%
RSI
44.22
Turnover
₹3.12 cr
Why it can matter in screens
- Momentum: NEPHROPLUS is below 50DMA, above 200DMA; RSI is 44.22.
- Returns: 1D +0.05%, 1W -1.58%, 1M -3.75%, 3M -9.31%, 1Y n/a.
- Trend levels: 52W high ₹781.50, 52W low ₹580.20, off high -20.08%.
- Liquidity: latest turnover is ₹3.12 cr; volume vs 20D is +0.33%.
- Valuation/profitability: PE 73.64, PB 5.61, ROE +10.01%, ROCE +16.24%.
- Growth: 3Y sales CAGR +34.06%, 3Y profit CAGR n/a.
Quick Answers
Is NEPHROPLUS above its 50DMA and 200DMA?
NEPHROPLUS is below 50DMA, above 200DMA. The latest 50DMA is 671.73 and the latest 200DMA is 619.12.
What are NEPHROPLUS PE, ROE and ROCE?
NEPHROPLUS has PE 73.64, ROE +10.01%, and ROCE +16.24% in Gimli's latest available snapshot.
How has NEPHROPLUS performed recently?
NEPHROPLUS has returned -3.75% over 1 month, -9.31% over 3 months, and n/a over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 281.75 cr | 67.78 cr | 31.97 cr | 3.19 |
| 2026-03-31 | 265.62 cr | 62.24 cr | 30.37 cr | 3.03 |
| 2025-12-31 | 259.73 cr | 64.18 cr | 32.24 cr | 3.43 |
| 2025-09-30 | 249.61 cr | 67.81 cr | -9.47 cr | nan |
| 2025-06-30 | 227.78 cr | 54.14 cr | 23.70 cr | 2.36 |
| 2025-03-31 | 219.19 cr | 55.41 cr | 24.87 cr | 2.48 |
| 2024-12-31 | 197.26 cr | 49.46 cr | 20.11 cr | 2.00 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 998.85 cr | 248.38 cr | 76.84 cr | 8.48 |
| 2025-03-31 | 755.81 cr | 180.74 cr | 67.10 cr | 6.69 |
| 2024-03-31 | 539.55 cr | 107.05 cr | 35.13 cr | 3.50 |
| 2023-03-31 | 414.52 cr | 52.87 cr | -11.79 cr | -1.17 |
| 2022-03-31 | 320.46 cr | 21.43 cr | -21.98 cr | -132.53 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 1,470.87 cr | 123.89 cr | 79.71 cr | 1,116.49 cr |
| 2025-03-31 | 996.46 cr | 125.82 cr | 257.78 cr | 584.11 cr |
| 2024-03-31 | 806.02 cr | 61.15 cr | 267.84 cr | 413.71 cr |
| 2023-03-31 | 666.23 cr | 13.19 cr | 213.73 cr | 388.63 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 232.58 cr | 113.22 cr | n/a |
| 2025-03-31 | 135.35 cr | 34.55 cr | n/a |
| 2024-03-31 | 72.28 cr | -7.72 cr | n/a |
| 2023-03-31 | 11.27 cr | -62.47 cr | n/a |
| 2022-03-31 | n/a | n/a | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-09-30 | +58.31% | +11.73% | +8.11% | +3.93% | +21.85% | +0.00% |
| 2026-06-30 | +63.85% | +8.78% | +9.05% | +3.20% | +18.32% | +0.00% |
| 2026-03-31 | +63.85% | +9.94% | +8.65% | +3.17% | +17.56% | +0.00% |
| 2025-12-31 | +63.85% | +9.30% | +8.10% | +3.10% | +18.74% | +0.00% |
| 2025-12-16 | +63.85% | +3.59% | +8.68% | +3.44% | +23.88% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 424,658.30 cr | 35.053345 | +15.50% | +3.72% |
| DIVISLAB | DIVI S LABORATORIES LTD | 267,167.60 cr | 91.684145 | +18.37% | +47.91% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,377.11 cr | 74.094685 | +16.87% | +28.16% |
| LAURUSLABS | LAURUS LABS LIMITED | 125,408.69 cr | 114.827348 | +21.77% | +138.16% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 124,833.39 cr | 27.818646 | +16.04% | +26.46% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 121,354.29 cr | 57.614911 | +22.62% | +7.87% |
| DRREDDY | DR. REDDY S LABORATORIES | 113,923.95 cr | 40.698752 | +7.80% | +14.41% |
| CIPLA | CIPLA LTD | 112,841.65 cr | 38.950805 | +8.80% | -7.58% |
Try these prompts
- Analyze NEPHROCARE HEALTH SERV L with valuation, momentum and industry peers
- Compare NEPHROPLUS with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare NEPHROPLUS with other Healthcare stocks
Data snapshot: 2026-11-03. Not investment advice.